A defining characteristic of inhaled drug delivery is variability in the dose received by the patient, as a result of physiology, for example, or the technique applied during use. This variability directly affects clinical outcomes so reducing it to a minimum is an important goal for the industry…
Being realistic about how patients use an inhaler and adopting designs that are as robust as possible is a valuable strategy for improving the efficacy of a therapeutic regime. Metered dose inhalers (MDIs) are often the front line treatment for asthma, chronic obstructive pulmonary disease and other respiratory illnesses. In daily use, such MDIs are naturally cycled through different temperatures as the patient moves from home to work or school and/or engages in outside activities. Ensuring that the device remains primed, in a ‘ready to use’ state, in the face of what can be substantial and sudden temperature changes is important to secure a clinically effective dose each time it is used.
In this article we explore the mechanisms of ‘loss of prime’ of an MDI as a result of temperature variations. Experimental work demonstrates the effect of exposure to different temperature cycles for three commercially available MDIs, formulated with different propellants. The implications of the results for clinical practice, patient experience and product design are examined.
Understanding MDIs: Priming and loss of prime
MDIs are formulated as either solution- or suspension-based products and deliver a reproducibly metered dose of medication, aerosolized by an evaporating propellant. Most commercial devices operate in a very similar way to the original 1950s push-and-breath design and rely on a relatively simple operating principle. Upon actuation, the metering chamber of the device becomes closed to the formulation reservoir, and open to the atmosphere. This results in expansion of the propellant-based formulation and atomization through the actuator orifice. The resulting aerosolized dose contains a significant fraction of drug particles in the fine particle fraction range (which is typically defined as having an upper aerodynamic particle diameter limit of 5µm).
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
A key component of an MDI is the capillary retention valve (Figure 1), which pre-meters the dose following actuation, preparing the inhaler for subsequent use. During this priming process, liquid formulation from the reservoir in the canister is driven through two capillaries, into the metering chamber, by the differential pressure across the valve stem orifice ports. The scientific basis for this design is sound, however, in certain circumstances opposing gravitational forces may exceed the capillary retention force (Rayleigh Taylor theory) causing drainage of the formulation from the metering chamber back into the canister1. Unless the MDI is re-primed prior to use, this effect can be a cause of erratic dosing.
Figure 1: Illustrative schematic of Bespak BK 357 MDI capillary valve (diameter of capillaries A & B = 0.6mm).
Exposure of the device to temperature changes also has the potential to influence prime by setting up temporary temperature gradients within the device. This is because the constituent components of the device are typically manufactured from different materials of construction and consequently heat up and cool down at different rates. A high thermal conductivity metal canister with insulating polymeric valve, for example, can result in the development of a high vapour pressure in the metering chamber, relative to the canister, which initiates drainage2. There is also evidence that such effects are influenced by the propellant used, with studies indicating that HFA 134a-based formulations may be more prone to loss of prime via this mechanism than those incorporating ethanol3. In the following studies, loss of prime as a result of temperature cycling was investigated for both HFA 134a formulations and those incorporating ethanol to elucidate these behaviours.
Case study: Assessing the impact of temperature cycling under controlled and realistic environmental conditions
Experiments were carried out to investigate the response to temperature cycling of three fixed-dose commercial MDIs; Foster® (Chiesi), Flutiform® (Mundipharma) and Seretide® (GlaxoSmithKline)4. Each of these products contains an inhaled corticosteroid (ICS) and a long-acting beta2 agonist (LABA) and uses a capillary retention valve for dose metering. However, each is different in terms of: the specific valve used, the nature of the formulation (solution or suspension) and the propellant/excipient mix (see Table 1). Five units of each MDI product, all within their use-by-dates, were used for testing.
Table 1: Summary of the container closure and formulation characteristics of three commercial MDIs used for dose retention testing.
Two real-world simulation cycles were applied to assess the effect of temperature variation on delivered shot weight; a third simulation subjected the MDIs to cycling under more closely controlled conditions (see Table 2). Each simulation involved cycling the MDI five times between two different environments, with all MDIs consistently stored valve-upwards when not in use.
Table 2: Temperature conditions for the environments used in product use simulations (n = 5).
To establish baseline standard shot weights (SSWs), each product was actuated – according to guidance in the patient instruction leaflets (PILs) – into dose unit sampling apparatus using standard pharmacopoeia test methods for dose uniformity testing for MDIs. Unprimed shot weight (USW) was measured after each temperature cycle, five in total for each simulation, in an analogous way. Dose retention values were calculated as the percentage ratio of the USW to SSW. In addition, the delivered dose of ICS and LABA was measured for five consecutive doses after Simulation 3 and subsequent storage (with the exception of LABA measurements for Seretide®).
Table 3 shows how the products vary in terms of dose retention as a result of exposure to temperature fluctuations. For the Foster® product, temperature changes of up to 15°C do not appear to affect USW/SSW, which remains constant throughout all three simulations. In contrast, the performance of flutiform® is only maintained during Simulation 1. When the temperature differential is increased to 15°C dose retention falls under both realistic and controlled conditions. With Seretide® the USW/SSW falls well below 100% as a result of the device being subjected to Simulation 1 and decreases further when temperature changes are increased to 15°C under realistic and controlled conditions (Simulations 2 and 3).
Table 3: % dose retention (USW/SSW) following different temperature cycling simulations (n = 5).
The more robust performance of Foster®, relative to the other two products, could be attributed to a relative high ethanol concentration (12%w/w), since this would concur with previous studies3. This explanation would also rationalise the intermediate performance of flutiform®, which contains 1.3%w/w ethanol compared with the Seretide®, which is an ethanol-free formulation. These results therefore suggest that the inclusion of ethanol as an excipient in an MDI formulation could aid the stabilisation of dose delivery with respect to temperature.
Figure 2: Delivered dose of ICS and LABA following Simulation 3 as a % ratio of the standard delivered dose as specified on the product label (n = 5).
Figure 2 shows how the delivered dose of the active ingredients in the formulation is affected by the closely controlled temperature cycling. Again, Foster® exhibits the most consistent performance with all of the ICS doses delivered to within 80-120% of the label claim. In contrast, the unprimed ICS delivered doses from flutiform® and Seretide® fall substantially below the label claim. The LABA data follows the same trends, where measured. Overall, for flutiform® and Seretide®, ten and eight doses, respectively, fell outside of the 80-120% label claim, with eight doses from the flutiform® product and five from the Seretide® falling outside of the 75-125% label claim (Table 4).
Table 4: Number of ICS and LABA doses measured outside of label claim following controlled cycling (Simulation 3). ND = not determined.
Interestingly, while the first unprimed shot following temperature cycling and storage delivered a dose lower than the label claim for flutiform® and Seretide®, the shot immediately following delivered a greater mass of ICS than the label claim. These results suggest that loss of prime is associated with the deposition of API in the metering chamber, which is then drawn into the subsequent dose as the metering chamber is refilled.
The number of doses falling outside the label claim for flutiform® and Seretide® is also noteworthy since the United States Food and Drug Administration guidelines recommend that no more than 1/10 delivered doses should be outside of the 80-120% label claim, for acceptable dose uniformity. Clearly these two products must be primed prior to use in order to meet this guideline, and this is reflected in the Patient Instruction Leaflet that accompanies them: a patient is instructed to fire up to four (flutiform) or two (Seretide) priming doses before taking their medication (120 dose label claim).
Furthermore, the flutiform PIL recommends priming not only before first use but also if the inhaler has not been used for three days or more, or exposed to freezing or refrigerated conditions. Seretide instructions are less explicit with regard to exposure to cold temperatures. However, these products are designed to be taken regularly twice a day, rather than as rescue inhalers, so exposure to temperature fluctuations and associated loss of prime is far less likely to be an issue.
Looking ahead
Designing more robust inhaled products that maintain consistency when subject to the rigours of routine daily use is an important goal for the industry. It is inevitable that patients will expose an MDI to modest temperature fluctuations, especially products that are used for acute symptom alleviation. The results presented here show that such fluctuations can cause dose drainage from the metering chambers of MDIs, loss of prime and the potential for sub-optimal dose delivery. This issue can be addressed by training patients to consistently prime an inhaler prior to use. However, the results reported here suggest that a more fundamental approach may be to manipulate formulation composition, most especially via excipient choice. Such findings open up a route to the development of MDIs that can perform more consistently and reliably in use, thereby offering more assured clinical efficacy.
Biography
DR DAVID LEWIS is Head of Laboratory at Chiesi’s research centre in Chippenham, UK. He holds a BSc in physics (1989) and MSc and PhD in aerosol science (1990 and 1994), from Essex University. David established the UK Research Centre in Chippenham, which opened in July 2009. He has authored over 130 research publications within the fields of pharmaceutics, analytical chemistry and aerosol science, and is co-inventor of 30 patents relating to pressurised metered dose inhaler formulations and devices.
References
Fradley G, Hodson D. Optimisation of fluid flow in pMDI valves. Respir. Drug Deliv. 2008; Vol 2, pp. 329-332
Fradley G, Hodson D. Optimisation of fluid flow in pMDI valves. Respir. Drug Deliv. 2008; Vol 2, pp. 329-332
Church TK, Hargrave GK, Johnson R, Lewis DA, O’Shea H, Versteeg HK. Visualising dose retention: fluctuation on a pMDI capillary retention model. Respir. Drug Deliv. 2011; 317-320
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.